Innate immunity activating drugs and their uses
Compounds of formula I address the limitations of recombinantly expressed interferons by inducing interferon production and acting as immune adjuvants, providing broad-spectrum antiviral and antitumor effects with enhanced immune responses and reduced side effects.
Patent Information
- Application Number
- JP2024535186
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-25
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current recombinantly expressed interferons are structurally unstable, require specific storage conditions, have short half-lives, and cause severe side effects at high concentrations, limiting their effectiveness in treating viral infections and tumors, while immune adjuvants face challenges in inducing robust immune responses with minimal side effects and cost.
Development of compounds of formula I, which can induce interferon production, act as broad-spectrum antivirals, and function as immune adjuvants, enhancing antibody production and tumor immunotherapy with minimal side effects and low production costs.
The compounds effectively induce interferon expression, inhibit viral infections, enhance antibody responses, and promote tumor immunotherapy, offering high medicinal efficacy with few side effects and potential for drug discovery.
Smart Images

Figure 2024543668000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicine, specifically, the present invention relates to innate immunity activating drugs with broad spectrum antiviral activity and for immunotherapy, antitumor and immune adjuvant and their applications. [Background technology]
[0002] Viral infection can cause various diseases, and innate immunity is the first natural defense of the host immune system against pathogenic microorganisms. Antiviral innate immune responses inhibit the growth and amplification of viruses by producing interferon in host cells, and viruses escape from the innate immune response during evolution. Therefore, the production of interferon by inducing the innate immune response provides a new idea for antiviral therapy.
[0003] At present, recombinantly expressed interferons are widely used in the treatment of viral infections, inflammation, immune dysfunction, etc., but they are protein polypeptides, without post-translational modification, unstable structure, cannot be taken orally, and have high storage requirements. They can only be administered by injection, and the administration method is single. In addition, their half-life is short, and at high concentrations, they may cause severe toxic side effects. The notable disadvantage of recombinantly expressed interferons in E. coli is that they lack glycosylation modification, which limits their activity, and the cost of expressing and purifying interferons with glycosylation using eukaryotic systems is high, and the price of drug discovery is also high.
[0004] In summary, there is an urgent need in the art for the development of new drugs that have the ability to induce interferon production.
[0005] In addition, the body's immune system can exert immune surveillance function to fight against tumors; on the one hand, the immune system can identify and specifically eliminate malignant cells through immune mechanisms to resist the development and progression of tumors; on the other hand, malignant cells can evade the body's immune surveillance through various mechanisms and rapidly proliferate in the body to form tumors. The development and outcome of tumors depend on the action results of these two aspects. As a tumor treatment drug, antibodies have better therapeutic effects due to their strong properties. In addition, during the process of antibody production in animals, due to factors such as the body's slow and poor immune response to antigens, the production of antibodies is low, thus limiting their use, and necessitating the action of immune adjuvants. Immune adjuvants, abbreviated as adjuvant, refer to auxiliary substances injected into the body before or simultaneously with antigens, which can enhance the body's immune response to antigens or change the type of immune response. The immunobiological effects of adjuvants include extending the retention time of antigens in the body, enhancing the processing and presentation of antigens, enhancing and strengthening the immune response, etc. Immune adjuvants have a wide range of applications due to their effect of enhancing immune response.Immune adjuvants must have the following characteristics: they have mild side effects on certain animals, their adjuvant effect lasts for a long time and is stable, their production cost should be as low as possible, and the immune response they produce must be appropriate, preferably capable of inducing cellular or humoral immunity in the body, and its strength can meet the protection requirements.Therefore, the development of novel immune adjuvants with high efficiency and low toxicity that can improve the body's immune level, cytokine secretion and immune memory is currently one of the hot research fields.
[0006] Thus, there is a need in the art to develop drugs that enhance tumor immunotherapy and function as immune adjuvants. Summary of the Invention [Problem to be solved by the invention]
[0007] The present invention aims to solve the technical problem of the lack of new drugs that can effectively improve the natural immunity of the human body, and to provide a natural immunity activating drug that can not only induce the production of interferon to fight viral infection, but also promote tumor immunotherapy and can be used as an immune adjuvant. [Means for solving the problem]
[0008] One aspect of the present invention provides the use of a compound of formula I or a tautomer, meso form, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, for preparing an innate immune activating drug. JPEG2024543668000002.jpg37170, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from hydrogen, halogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an amino group, a hydroxy group, a mercapto group, a carboxy group, an alkoxy group, a cycloalkoxy group, a halogenated alkyl group, a cyano group, a sulfanyl group, a sulfonyl group, a sulfone group, a sulfoxide group, and a phosphate group, and the alkyl group, the cycloalkyl group, the alkoxy group, the cycloalkoxy group, the amino group, the heterocyclyl group, the aryl group, or the heteroaryl group may be substituted with one or more substituents, and the substituents ... or is selected from one or more of the following substituents: alkyl, cycloalkoxy, heterocyclyl, aryl, halogenated aryl, halogenated alkyl, heteroaryl, alkenyl, alkynyl, amino, mercapto, carboxy, ester, alkoxycarbonyl, acyloxy, acylamino, carbamide, alkylsulfonyl, aromaticsulfonyl, cyano, nitro, nitroso, thiocyanato, isothiocyanato, sulfanyl, sulfonyl, phosphate, phosphonate, alkylphosphate, alkylphosphonate, arylphosphate, arylphosphonate, or is null, and said heterocyclyl group contains at least one N atom or contains 1, 2 or 3 heteroatoms arbitrarily selected from N, S and O.
[0009] Here, the term "substituted" refers to one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group being replaced by a substituent selected from the group consisting of a hydroxy group, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a cycloalkoxy group, a heterocyclyl group, an aryl group, a halogenated aryl group, a halogenated alkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, an amino group, a mercapto group, a carboxy group, an ester group, an alkoxycarbonyl group, an acyloxy group, an acylamino group, a carbamide group, an alkylsulfonyl group, an aromatic sulfonyl group, a cyano group, a nitro group, a nitroso group, a thiocyanato group, an isothiocyanato group, a sulfanyl group, a sulfonyl group, a phosphate group, a phosphonic acid group, an alkyl phosphate group, an alkyl phosphonic acid group, an aryl phosphate group, and an aryl phosphonic acid group.
[0010] The heteroaryl group has 1 to 4 (preferably 1, 2, 3 or 4) heteroatoms selected from N, O and S on the heterocycle.
[0011] In another preferred example, R1, R2, R5, R7, and R10 are each independently hydrogen, a substituted or unsubstituted C1-C10 alkyl group, or a substituted or unsubstituted C3-C12 cycloalkyl group.
[0012] In another preferred example, R1, R2, R5, R7, and R10 are each independently hydrogen, a substituted or unsubstituted C1-C8 alkyl group, or a substituted or unsubstituted C3-C8 cycloalkyl group.
[0013] In another preferred example, R1, R2, R5, R7, and R10 are each independently hydrogen, a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted C3-C8 cycloalkyl group.
[0014] In another preferred example, R1, R2, R5, R7, and R10 are each independently hydrogen, a substituted or unsubstituted C1-C4 alkyl group, or a substituted or unsubstituted C3-C8 cycloalkyl group.
[0015] In another preferred example, R1, R2, R5, R7, and R10 are each independently a hydrogen atom, a methyl group, an ethyl group, a propyl group, or a butyl group.
[0016] In another preferred example, R3 and R4 are each independently hydrogen, a substituted or unsubstituted C1-C8 alkoxy group, or a substituted or unsubstituted C1-C8 alkylthio group.
[0017] In another preferred example, R3 and R4 are each independently hydrogen, a substituted or unsubstituted C1-C6 alkoxy group, or a substituted or unsubstituted C1-C6 alkylthio group.
[0018] In another preferred example, R3 and R4 are each independently hydrogen, a substituted or unsubstituted C1-C4 alkoxy group, or a substituted or unsubstituted C1-C4 alkylthio group.
[0019] In another preferred example, R3 and R4 are each independently hydrogen, a substituted or unsubstituted C1-C2 alkoxy group, or a substituted or unsubstituted C1-C2 alkylthio group.
[0020] In another preferred example, R6 is a substituted or unsubstituted amino group, a substituted or unsubstituted heterocyclyl group, a heterocyclyl group alkyl group, or an alkyl group heterocyclyl group.
[0021] In another preferred example, R8 is a halogenated alkyl group.
[0022] In another preferred example, R9 is hydrogen, a halogen, or an amino group.
[0023] In another preferred embodiment, the compound of formula I includes the following compounds: JPEG2024543668000003.jpg33170JPEG2024543668000004.jpg169170
[0024] Preferably, the pharma- ceutically acceptable salts of the compounds of formula I include the following salts: JPEG2024543668000005.jpg64170JPEG2024543668000006.jpg41170
[0025] Preferably, the innate immune activating drug is (a) a broad-spectrum antiviral drug; (b) an antitumor drug; (c) a drug for preventing and / or treating cancer; (d) a drug for treating or preventing a type I interferon-associated disease; (e) an immune adjuvant; and and / or (f) a cytokine-inducing agent. In another preferred embodiment, the cytokine is selected from the group consisting of an interferon, a tumor necrosis factor, an interleukin, or a combination thereof.
[0026] In another preferred embodiment, the interferon is selected from the group consisting of a type I interferon, a type II interferon, a type III interferon, or a combination thereof.
[0027] In another preferred embodiment, the interferon is selected from the group consisting of IFNβ (interferon-β), IFNλ (interferon-lambda), TNFα (tumor necrosis factor-α), or a combination thereof.
[0028] In another preferred embodiment, the interleukin is selected from the group consisting of IL6 (interleukin-6), IL1α (interleukin-1α), or a combination thereof.
[0029] In another preferred embodiment, the cytokines include cytokines in blood, serum or plasma.
[0030] In another preferred embodiment, the cytokine inducer increases the level or content of the cytokine.
[0031] In another preferred embodiment, the blood includes peripheral blood.
[0032] In another preferred embodiment, the inducer is (I) Induction of cytokine expression, and / or (I) Induction of increased cytokine content.
[0033] In another preferred embodiment, the inducing agent comprises inducing an increase in a cytokine in peripheral blood.
[0034] In another preferred embodiment, the adjuvant comprises an antibody adjuvant.
[0035] In another preferred embodiment, the immune adjuvant is used to enhance the immune titer of an antibody.
[0036] In another preferred example, the immune adjuvant is used to promote antibody production or as an antibody production promoter.
[0037] In another preferred embodiment, the antibody comprises a serum antibody.
[0038] In another preferred embodiment, the antigen against which the antibody is directed comprises a protein antigen.
[0039] In another preferred embodiment, the protein antigen comprises an albumin antigen.
[0040] In another preferred embodiment, the albumin antigen comprises an ovalbumin antigen.
[0041] In another preferred embodiment, the immune adjuvant is used to prepare an antibody, a vaccine, an immunotherapeutic agent and / or an immune activator.
[0042] In another preferred embodiment, the antibody is selected from the group consisting of IgG, IgM, or a combination thereof.
[0043] In another preferred embodiment, the IgG comprises IgG1.
[0044] In another preferred embodiment, the vaccine comprises a tumor vaccine.
[0045] In another preferred embodiment, said type I interferon-associated disease refers to a disease that is ameliorated, treated or prevented by increasing the level of type I interferon in the body.
[0046] In another preferred embodiment, said type I interferon (IFN) associated disease comprises viral infection, and multiple sclerosis and / or chronic myeloid leukemia.
[0047] In another preferred embodiment, the virus comprises a DNA virus and an RNA virus.
[0048] In another preferred embodiment, said DNA virus comprises HSV (Herpes Simplex Virus), HBV (Hepatitis B Virus), HAV (Hepatitis A Virus), HPV (Human Papilloma Virus) and / or EBV (Epstein-Barr Virus).
[0049] In another preferred embodiment, the RNA virus comprises VSV (vesicular stomatitis virus), HCV (hepatitis C virus), EMCV (encephalomyocarditis virus), Ebola, HIV (AIDS virus) and / or Zika virus.
[0050] Another aspect of the present invention further provides a method of inducing the production of type I interferon in a subject, said method comprising the step of contacting the subject with a compound of formula I, thereby inducing the production of type I interferon in said subject.
[0051] In another preferred embodiment, the subject is a cell.
[0052] In another preferred example, the cells include Vero cells, THP-1 cells, HEK293 cells, HEK293T cells, and / or A549 cells.
[0053] In another preferred embodiment, the method is in vitro and non-therapeutic.
[0054] In another preferred example, the method comprises the step of incubating the subject with a system containing a compound of formula I, thereby inducing the production of interferon in the subject.
[0055] In another preferred example, in the system containing the compound of formula I, the concentration of the compound of formula I is ≧1 μM, preferably ≧3 μM.
[0056] In another preferred example, the incubation time is from 10 minutes to 48 hours.
[0057] In another preferred embodiment, the type I interferon comprises IFNβ.
[0058] Another aspect of the invention further provides a method of inhibiting a viral infection, comprising: The method includes the step of contacting a subject with a compound of formula I, thereby inhibiting infection of the subject with the virus.
[0059] In another preferred embodiment, the subject is a cell.
[0060] In another preferred example, the cells include Vero cells, THP-1 cells, HEK293 cells, HEK293T cells, and / or A549 cells.
[0061] In another preferred embodiment, the virus comprises a DNA virus and an RNA virus.
[0062] In another preferred embodiment, the DNA virus includes HSV (herpes simplex virus), HBV (hepatitis B virus), HAV (hepatitis A virus), HPV (human papilloma virus) and / or EBV (Epstein-Barr virus), and the like.
[0063] In another preferred example, the RNA virus includes VSV (vesicular stomatitis virus), HCV (hepatitis C virus), EMCV (encephalomyocarditis virus), Ebola virus, HIV (AIDS virus) and / or Zika virus, etc.
[0064] In another preferred embodiment, the method is in vitro and non-therapeutic.
[0065] In another preferred example, the method comprises the step of incubating the subject with a system containing a compound of formula I, thereby inducing the production of interferon in the subject.
[0066] Another aspect of the present invention further provides a method of increasing the level of type I interferon in the body, said method comprising administering to a subject in need thereof a compound of formula I, or a pharma- ceutically acceptable salt thereof.
[0067] In another preferred embodiment, the subject is a mammal, preferably selected from the group consisting of a human, a mouse, and a rat.
[0068] Another aspect of the present invention further provides a broad spectrum antiviral pharmaceutical composition, said pharmaceutical composition comprising a compound of formula I or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0069] Another aspect of the present invention further provides an immunological composition, said immunological composition comprising a compound of formula I or a tautomer, meso form, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, and an antigen.
[0070] In another preferred embodiment, the antigen comprises a protein antigen.
[0071] In another preferred embodiment, the protein antigen comprises an albumin antigen.
[0072] In another preferred embodiment, the albumin antigen comprises an ovalbumin antigen.
[0073] Another aspect of the present invention provides an antitumor pharmaceutical composition comprising a compound of formula I or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0074] Another aspect of the present invention further provides a composition, said composition comprising: (a) a first active ingredient which is a compound represented by Formula I, or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof; and (b) a therapeutically effective amount of a second active ingredient comprising an immunotherapy activator, a type I interferon modulating agent, or an antiviral agent.
[0075] Another aspect of the invention further provides a kit, said kit comprising: (A) a first formulation comprising a first active ingredient which is a compound represented by formula I, or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof; and (B) a second formulation comprising a second active ingredient comprising an immunotherapy activator, a type I interferon modulating agent, or an antiviral agent.
[0076] In another preferred embodiment, the immunotherapy activator comprises PD-1 or PD-L1 antibody, and the combination of the compound represented by Formula I of the present invention and PD-1 or PD-L1 antibody exerts a synergistic effect, which significantly enhances the inhibitory effect on tumor growth and greatly improves survival time.
[0077] Another aspect of the present invention further provides a use of the above composition or the above kit for preparing a natural immune activating drug, the drug comprising: (a) a broad-spectrum antiviral drug; (b) an antitumor drug; (c) a drug for preventing and / or treating cancer; (d) a drug for treating or preventing a type I interferon-associated disease; (e) an immune adjuvant; and and / or (f) a cytokine-inducing agent. Effect of the Invention
[0078] The main advantages of the innate immunity activating drug of the present invention are as follows: (a) The present inventors have found that compounds of formula I exhibit potent ability to induce expression of interferons (eg, IFNβ). (b) The present inventors have found that compounds of formula I have excellent ability to inhibit viral infections and have antiviral activity. (c) The present invention has found that compounds of formula I efficiently and safely induce cytokine production and can therefore be used to treat cytokine-associated diseases such as tumors. (d) The present invention has found that the compound of formula I can be used as an immune adjuvant, which can significantly increase the immune titer of antibody and promote the production of antibody, and thus can be used in the preparation of antibodies, vaccines, immunotherapeutic drugs and immune activators, thereby enhancing the application value of antibodies. (e) The compounds described in the present invention have high efficacy, high drug potential, and few side effects.
[0079] It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (e.g., in the embodiments) can be combined with each other to form new or preferred technical solutions, which will not be repeated here due to space limitations. [Brief description of the drawings]
[0080] The present invention will now be described in more detail in conjunction with the accompanying drawings and specific embodiments. [Figure 1] FIG. 1 shows the results of transcriptional activation of type I interferon and interleukin-6 in HEK293T cells after treatment with compounds LD001 to LD004 at a final concentration of 10 μM for 12 hours in Example 1 of the present invention. [Diagram 2] FIG. 2 shows the results of transcriptional activation of type I interferon and interleukin-6 in HeLa cells after treatment with compounds LD001 to LD004 at a final concentration of 10 μM for 12 hours in Example 1 of the present invention. [Diagram 3] FIG. 2 shows the results of transcriptional activation of type I interferon and interleukin-6 in A549 cells after treatment with compounds LD001 to LD004 at a final concentration of 10 μM for 12 hours in Example 1 of the present invention. [Figure 4] FIG. 1 shows the results of transcriptional activation of type I interferon and interleukin-6 in HEK293T cells after treatment with compounds LD005 to LD011 at a final concentration of 10 μM for 12 hours in Example 1 of the present invention. [Diagram 5] FIG. 2 shows the results of transcriptional activation of type I interferon and interleukin-6 in PEM cells after treatment for 12 hours with compounds LD005 to LD011 each at a final concentration of 10 μM in Example 1 of the present invention. [Figure 6]FIG. 13 is an inhibition curve diagram of LD002 against VSV-GFP in Example 2 of the present invention. [Figure 7] FIG. 2 is an inhibition curve diagram of LD002 against H1N1-IAV in Example 2 of the present invention. [Figure 8] FIG. 1 shows an inhibition curve of LD002 against HSV in Example 3 of the present invention. [Figure 9] FIG. 1 shows the results of an ELISA test of compound LD002, which induces interferon production in mice, in Example 4 of the present invention. [Figure 10] FIG. 1 shows the experimental results of administering compound LD002 alone to inhibit melanoma growth in Example 5 of the present invention. [Figure 11] FIG. 5 is an experimental result diagram showing that compound LD002 is co-administered with another immunotherapy activator, anti-PD-L1, to inhibit melanoma growth in Example 5 of the present invention. [Figure 12] FIG. 1 shows the results of an ELISA method for testing whether the compound of the present invention has immune adjuvant activity in Example 6 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0081] As a result of extensive and detailed research, the present inventors have found that a certain class of three-membered heterocyclic compounds can activate the host's innate immunity and induce various cells to express or produce cytokines such as type I interferon IFNβ. In addition, this class of compounds has a broad-spectrum inhibitory effect (dose-dependent) against RNA virus (e.g., VSV) and DNA virus (e.g., HSV) infection. This provides a new drug that induces the production of IFNβ by cells and is expected to have a broad-spectrum antiviral effect in clinical treatment. It has been unexpectedly found that the compound of formula I described in the present invention has an excellent induction effect on cytokines and can be used to treat diseases such as tumors. At the same time, the compound of formula I described in the present invention can also be used as an immune adjuvant to significantly increase the immune titer of antibodies and promote the production of antibodies, which can be used in the preparation of antibodies, vaccines, immunotherapeutic drugs and immune activators to enhance the application value of antibodies.
[0082] natural immunity The host's innate immunity is the first line of defense of the immune system against pathogenic microorganisms. Viruses in nature are pathogens that can cause various diseases, and the innate immune response of host cells to viruses induces the production of interferon to inhibit the growth and amplification of viruses. The antiviral innate immune response is mediated by signal transduction pathways. Previous studies have revealed how the innate immune system identifies viral invasion and rapidly activates immune defense functions to effectively eliminate viral infections. This is an important study in the fields of life science and medicine, providing a theoretical basis for the design of related drugs and bringing new hope for the prevention and treatment of viral infections. After detecting pathogenic microorganisms, host cells induce the production of interferons, pro-inflammatory factors and chemokines through innate immune signaling pathways, while these effectors can inhibit the replication of pathogens, thereby rapidly controlling their growth. Meanwhile, these cytokines recruit antigen-presenting cells of the adaptive immune system and other immune cells of the host, such as T and B lymphocytes, to activate adaptive immunity. Moreover, the induction and activation of innate immune responses further has antitumor effects and can enhance the efficacy of radiotherapy and chemotherapy.
[0083] Innate immune signaling pathways begin with the recognition of pathogenic microorganism-associated molecular patterns by host cell pattern recognition receptors. The viral infection-related innate immune signaling pathways discovered so far mainly include the RLR-MAVS signaling pathway, which recognizes RNA viruses in the cytoplasm, and the cGAS-STING signaling pathway, which recognizes DNA viruses, as well as the TLRs signaling pathway. After both RLRs and cGAS signaling pathways are activated, they recruit and activate TBK1 through downstream transduction proteins, which phosphorylate the transcription factor IRF3 to enter the nucleus and induce the production of type I interferon, ultimately achieving the effect of inhibiting the virus. During the long-term evolutionary process, some viruses have also acquired mechanisms to escape from innate immune responses.
[0084] Because innate immunity plays a key role in all aspects of the body's vital activities, it is an important guide in the research and preparation of vaccines and in the development of drugs.
[0085] term Active ingredient As used herein, the term "compounds of the invention" refers to compounds represented by Formula I. The term further includes various crystal forms, pharma- ceutically acceptable salts, isomers, hydrates, solvates or prodrugs of the compounds of Formula I.
[0086] Here, the term "medicinal salt" or "pharmaceutical acceptable salt" refers to a salt formed by the compound of the present invention with an acid or base that is suitable for use as a drug. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts is the salt formed by the compound of the present invention with an acid. Acids suitable for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, etc., organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, etc., and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid, etc. Further preferred salts are salts formed by the compounds of the present invention with bases, such as alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., magnesium or calcium salts), ammonium salts (e.g., lower alkanol ammonium salts and other pharma- ceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, t-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.
[0087] The compound of formula I according to the present invention can be converted into its pharma-ceutically acceptable salt by conventional methods.For example, a corresponding acid solution can be added to the solution of the compound, and after the formation of the salt is completed, the solvent can be removed to obtain the corresponding salt of the compound according to the present invention.
[0088] As used herein, the term "prodrug" includes prodrugs which may themselves be biologically active or inactive and, after appropriate ingestion, are converted in the human body through metabolism or chemical reaction to a compound of formula I, or a salt or solution consisting of a compound of formula I. The prodrugs include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfonate, sulfoxide ester, amino compounds, carbamates, azo compounds, phosphoramides, glucosides, ethers, acetals, and the like forms of the compound.
[0089] First active ingredient The first active ingredient of the present invention is a compound of formula I, or a pharma- ceutically acceptable salt thereof, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a prodrug thereof.
[0090] As used herein, "a compound of the invention," "a compound of formula I of the invention," or "a compound of formula I" are used interchangeably and refer to a compound of formula I, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof. It is to be understood that the term further includes mixtures of the above components. JPEG2024543668000007.jpg38170 In formula I, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from hydrogen, halogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an amino group, a hydroxy group, a mercapto group, a carboxy group, an alkoxy group, a cycloalkoxy group, a halogenated alkyl group, a cyano group, a sulfanyl group, a sulfonyl group, a sulfone group, a sulfoxide group, and a phosphate group, and the alkyl group, the cycloalkyl group, the alkoxy group, the cycloalkoxy group, the amino group, the heterocyclyl group, the aryl group, or the heteroaryl group may be substituted with one or more substituents, and the substituents ... or is selected from one or more of the following substituents: alkyl, cycloalkoxy, heterocyclyl, aryl, halogenated aryl, halogenated alkyl, heteroaryl, alkenyl, alkynyl, amino, mercapto, carboxy, ester, alkoxycarbonyl, acyloxy, acylamino, carbamide, alkylsulfonyl, aromaticsulfonyl, cyano, nitro, nitroso, thiocyanato, isothiocyanato, sulfanyl, sulfonyl, phosphate, phosphonate, alkylphosphate, alkylphosphonate, arylphosphate, arylphosphonate, or is null, and said heterocyclyl group contains at least one N atom or contains 1, 2 or 3 heteroatoms arbitrarily selected from N, S and O.
[0091] Preferred compounds of the present invention include the following compounds: JPEG2024543668000008.jpg216170
[0092] Pharmaceutically acceptable salts of preferred compounds of the invention include the following salts: JPEG2024543668000009.jpg108170
[0093] Second active ingredient The second active ingredient of the present invention is an antiviral, antitumor, immunomodulatory and immunoadjuvant drug, which can be used in combination with PD-1 or PD-L1 antibodies for immunotherapy.
[0094] As used herein, the term "PD-L1" refers to programmed cell death-ligand 1, an important immune inhibitory molecule; PD-L1 is expressed on the surface of tumors, binds to PD-1 on the surface of T cells, inhibits T cell proliferation and cytokine secretion, negatively regulates lymphocyte activation, and is involved in tumor immune evasion.
[0095] Pharmaceutical Compositions and Methods of Administration The compound of the present invention has excellent ability to induce the production of type I interferon, so the compound of the present invention and its various crystal forms, pharma-ceutically acceptable inorganic or organic salts, hydrates or solvates, as well as pharmaceutical compositions containing the compound of the present invention as the main active ingredient, can be used to treat, prevent and alleviate type I interferon-related diseases (particularly, diseases that can be improved, treated or prevented by regulating the interferon level in the body, such as increasing the interferon level).According to the prior art, the compound of the present invention can be used to treat diseases such as viral infections, multiple sclerosis, systemic lupus erythematosus and chronic myeloid leukemia.
[0096] As used herein, the terms "inducing the production of interferon," "inducing the production of type I interferon," "induction of the production of type I interferon," or "induction of the production of interferon" are used interchangeably and are intended to include increasing the expression, transcription or protein content levels, etc. of type I interferon or type I interferon-related proteins, cytokines, etc.
[0097] The pharmaceutical composition of the present invention contains a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Here, "safe and effective amount" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound / agent of the present invention, more preferably 10-500 mg of the compound / agent of the present invention. Preferably, the "one agent" is one capsule or tablet.
[0098] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be suitable for human use, have sufficient purity and sufficiently low toxicity. "Compatibility" refers to the ability of the components of the composition to be blended with each other without significantly reducing the efficacy of the compounds of the present invention and between them. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween R), wetting agents (e.g., sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0099] The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and topical administration.
[0100] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as, for example, sodium citrate or dicalcium phosphate, or with ingredients such as (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) retarding agents, such as paraffin; (f) absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0101] Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coating and shell materials, such as enteric coatings and other materials known in the art. They can contain opacifying agents, and the release of the active compound or compounds of such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can be formed into microcapsules with one or more of the above-mentioned excipients.
[0102] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms can contain inert diluents conventionally used in the art, such as water or other solvents, and solubilizers and emulsifiers, such as, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.
[0103] Besides these inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0104] In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide, and agar-agar, or mixtures of these substances.
[0105] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0106] Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required.
[0107] The compounds of the present invention can be administered alone or in combination with other pharma- ceutically acceptable compounds.
[0108] When a pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., human) in need of treatment, where the dosage at the time of administration is the effective dosage considered, and for a person weighing 60 kg, the daily dosage is usually 1-2000 mg, preferably 20-500 mg. Of course, the specific dosage must also take into account factors such as the route of administration and the health condition of the patient, all of which are within the skill of a skilled physician.
[0109] Compositions or formulations, combinations of active ingredients and kits and methods of administration The present invention further provides compositions or formulations, active ingredient combinations and kits, which can be used to prepare innate immune activating drugs, comprising (a) a broad-spectrum antiviral drug, (b) an antitumor drug, (c) a drug for preventing and / or treating cancer, (d) a drug for treating or preventing type I interferon-associated diseases, (e) an immune adjuvant, and / or (f) a cytokine inducer.
[0110] The composition according to the present invention is preferably a pharmaceutical composition. The composition according to the present invention may include a pharma- ceutically acceptable carrier.
[0111] Drug formulations should be compatible with the method of administration, and preferred methods of administration are oral administration, injection administration (e.g., intratumoral injection), and when used, a therapeutically effective amount of drug is administered to a subject (e.g., a human or non-human mammal) in need thereof. As used herein, the term "therapeutically effective amount" refers to an amount that produces a function or activity in humans and / or animals and is tolerated by humans and / or animals. Those skilled in the art should understand that the "therapeutically effective amount" may vary depending on circumstances such as the form of pharmaceutical composition, the route of administration, the excipient of the drug used, the severity of the disease, and co-administration with other drugs.
[0112] In one administration method, the safe and effective daily dose of the first active ingredient is usually at least about 0.1 mg, and in most cases does not exceed about 2500 mg. Preferably, the dose is 1 mg to 500 mg, and the safe and effective amount of the second active ingredient is usually at least about 0.01 mg, and in most cases does not exceed 2500 mg. Preferably, the dose range is 0.1 mg to 2500 mg. Of course, the specific dose should also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.
[0113] Example 1. Compounds of the invention induce cellular secretion of interferon First, the activity of the following 11 newly synthesized small molecule compounds (LD001 to LD011) to induce the production of type I interferon in various types of cells such as HEK293T, HeLa, A549, and PEM was measured. JPEG2024543668000010.jpg124170JPEG2024543668000011.jpg55170JPEG2024543668000012.jpg97170
[0114] The 293T, HeLa and A549 cell lines used were all purchased from the Cell Bank of Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences. Monolayers were cultured at 37°C in a 5% CO2 incubator, and cells were grown in DMEM medium containing 10% FBS and 100 U / ml penicillin and 100 μg / ml streptomycin. PEM cells are macrophages isolated from the peritoneal cavity of C57BL / 6 mice.
[0115] Various cells in the logarithmic growth phase, such as HEK293T, HeLa, A549, and PEM, were seeded into 12-well cell culture plates at a seeding density of 80-90%. After the cells were allowed to adhere to the walls for 6 hours, the cell culture supernatant was replaced with a medium containing various low molecular weight compounds, LD001 to LD011, at a final concentration of 10 μM. The cells were then cultured for 12 hours. Finally, the cells were harvested and total cellular RNA was extracted.
[0116] Then, qPCR was used to measure the transcription activation of type I interferon and interleukin-6 induced by various cells during drug treatment. The results showed that LD002 could significantly promote the transcription of type I interferon in three types of cells, including HEK293T, HeLa, and A549, and at the same time, the transcription level of interleukin-6 was also increased to a certain extent (Figure 1, Figure 2, and Figure 3). Furthermore, the results showed that LD007 and LD010 could significantly induce the expression of type I interferon in HEK293T and PEM cells, and LD005 could significantly induce the expression of type I interferon in PEM cells (Figure 4 and Figure 5). In summary, Figures 1-5 show that compounds LD001-LD011 have the activity of inducing the expression of type I interferon or interleukin-6 in HEK293T, HeLa, A549, or PEM cells. Considering that LD007 and LD010 have inhibitory effects on cell proliferation and exhibit strong cytotoxicity, and LD005 has low solubility in PBS, the present invention selected compound LD002 as a representative compound to carry out the studies in the subsequent examples.
[0117] Example 2. Inhibition of the inventive compound LD002 against RNA viruses (VSV and H1N1-IAV) The results of the previous Example 1 demonstrated that LD002 can significantly induce the expression of type I interferon in cells. Next, a virus cell infection model was used to measure the inhibitory effect of LD002 on virus amplification. Vesicular stomatitis virus (VSV) and influenza virus (IAV) were selected as representatives of RNA viruses. Specifically, VSV-GFP and H1N1 virus strains were used. VSV-GFP itself can express green fluorescent protein GFP, which is useful for indicating virus growth and load.
[0118] A549 cells in logarithmic growth phase were seeded in 12-well cell culture plates at an inoculation density of 80-90%, and the cells were allowed to adhere to the wall for 6 hours, after which a dilution of VSV virus at a multiplicity of infection (MOI) of 0.5 was added. One hour after virus infection, the cells were treated with various concentrations of the compound of the present invention LD002, and 12 hours later, total cellular RNA was extracted and the virus amplification status was measured. Based on the degree of inhibition of VSV-GFP infection after treating A549 cells with various concentrations of LD002, the EC 50 The median effective concentration was calculated to be 1.789, and the selectivity index (SI) was 135.1 (FIG. 6). The results show that the compound of the present invention has excellent anti-VSV virus activity and safety.
[0119] Similarly, logarithmic growth phase A549 cells were seeded in 12-well cell culture plates at an inoculation density of 80-90%, and the cells were allowed to adhere to the wall for 6 hours, after which a dilution of H1N1-IAV virus with a multiplicity of infection (MOI) of 0.5 was added. One hour after virus infection, the cells were treated with various concentrations of the compound LD002 of the present invention, and 12 hours later, total cellular RNA was extracted and the virus amplification status was measured. Based on the degree of inhibition of H1N1-IAV infection after treating A549 cells with various concentrations of LD002, the inhibitory effect EC of LD002 on H1N1-IAV infection was evaluated. 50 The median effective concentration was calculated to be 4.735, and the selectivity index (SI) was 52.79 (FIG. 7). The results show that the compound of the present invention has good anti-IAV virus activity and safety.
[0120] Example 3. Inhibitory effect of the compound of the present invention, LD002, on DNA virus (e.g., HSV) infection Herpes simplex virus HSV was selected as a representative of DNA viruses. Specifically, the HSV-1-GFP virus strain was used, which is capable of expressing green fluorescent protein GFP, which can indicate viral growth and load.
[0121] A549 cells in logarithmic growth phase were seeded in 12-well cell culture plates at an inoculation density of 80-90%, and the cells were allowed to adhere to the wall for 6 hours, after which a dilution of HSV virus at a multiplicity of infection (MOI) of 0.5 was added. One hour after virus infection, the cells were treated with various concentrations of the compound of the present invention LD002, and 12 hours later, total cellular RNA was extracted and the virus amplification status was measured. Based on the degree of inhibition of HSV-GFP infection after treating A549 cells with various concentrations of LD002, the EC 50 The median effective concentration was calculated to be 1.948, and the selectivity index (SI) was 123.92 (FIG. 8). The results show that the compound of the present invention has excellent anti-HSV virus activity and safety.
[0122] Example 4. Compound LD002 of the present invention induces interferon production in mice The mice used in all experiments were 6-8 week-old male C57BL / 6 mice provided by the Animal Experimental Technology Platform of the Center for Excellence and Innovation in Molecular and Cellular Sciences. The mice were intraperitoneally injected with various doses (100 μg or 300 μg) of the compound LD002 of the present invention, and 6 hours later, the changes in the content of various cytokines in the serum were measured using ELISA. The results show that the experimental group of the compound LD002 of the present invention can significantly increase the levels of type I interferon IFNβ (interferon-β) and IL1β (interleukin-1β) in the serum, and can slightly increase the expression levels of IL-6 (interleukin-6), TNFα (tumor necrosis factor-α) and type III interferon IFNλ (interferon-λ) (Figure 9). In Figure 9, Ctrl is the control group injected intraperitoneally with PBS, and the injection volume is 100 μL / mouse.
[0123] Example 5. Compound LD002 of the present invention has antitumor effects and the function of promoting tumor immunotherapy 1. Method The B16-F10 melanoma cell line used in this experiment was purchased from Shanghai Cell Bank, Chinese Academy of Sciences, and routinely cultured in DMEM medium containing 10% FBS in a 5% CO2 incubator at 37 °C. Exponentially growing cells were digested with 0.25% trypsin, resuspended in PBS after centrifugation, and counted to detect a viable cell rate of 95% or higher. After counting, the concentration of the cell suspension was adjusted to 2 × 10 6 The volume was adjusted to mL-1. The resuspended tumor cells were dispensed into sterile EP tubes and kept on ice until use.
[0124] The back of the mouse was depilated using an electric shaver. The depilated area was approximately 9 cm 2 The B16-F10 cells prepared above were harvested and 100 μL of the tumor cell suspension was subcutaneously injected into the back of each mouse. The mice were observed daily for tumor growth, and on the fourth day, melanoma formation was macroscopically observed. Tumor-free mice were excluded, and the remaining mice were randomly divided into seven groups, with five mice in each experimental group.
[0125] The first experimental group was divided into a control group, a group of 100μg of the compound LD002 of the present invention, and a group of 300μg of the compound LD002 of the present invention, and the second experimental group was divided into a control group, a group of 100μg of the compound LD002 of the present invention, a group of 200μg of anti-PD-L1 antibody (B7-H1) (clone: 10F.9G2), and a group of 100μg of the compound LD002 of the present invention + 200μg of anti-PD-L1 antibody (B7-H1) (clone: 10F.9G2), with 6-8 mice per group. The experimental method was as follows: 5 days after tumor cell injection, tumor-bearing mice were administered according to grouping, LD002 was intraperitoneally injected, and two dose groups were set at 100μg / mouse and 300μg / mouse. Anti-PD-L1 antibody was administered by intraperitoneal injection, and one dose group was set at 200μg / mouse. The solvent buffer system used was PBS buffer solution. The control group was forced to receive the same volume of PBS buffer solution. The compound drugs of the present invention were administered to each mouse once every two days for a total of three times. The administration volume was 100μL for all. The anti-PD-L1 antibody was administered to each mouse once every two days for a total of three times. The administration volume was 50μL. Specifically, the drugs were administered on the 5th, 7th, and 9th days, respectively, and administered twice at two-day intervals. The tumor size was measured every other day, the survival time of the mice was recorded, and the relevant data was recorded, and the tumor volume was measured using an electronic caliper. The volume was calculated as π / 6×length×width×height. If the tumor volume was 2000mm 3 If the tumor-bearing mice exceeded the threshold, they were sacrificed.
[0126] 2. Experimental Results The compound of the present invention, LD002, inhibits the growth of subcutaneous melanoma in mice and improves survival of tumor-bearing mice.
[0127] By establishing a subcutaneous melanoma tumor-bearing mouse model, the inhibitory effects of the inventive compounds LD002 and LD002+anti-PD-L1 on tumor growth and improved survival of tumor-bearing mice were observed. The results showed that compared with the control group, single administration of the inventive compounds had a significant dose-dependent inhibitory effect on melanoma growth and improved survival of tumor-bearing mice (Figure 10).
[0128] Compared with the control group and the single administration of the compound of the present invention LD002, anti-PD-L1 can significantly enhance the inhibitory effect of the compound of the present invention on melanoma growth and improve the survival time of mice. The result data showed that the compound of the present invention LD002 and anti-PD-L1 can jointly exert a synergistic effect, and the inhibitory effect of melanoma growth and the improvement of the survival time of mice are more significant (Figure 11).
[0129] From Examples 4 and 5, it can be seen that the compound LD002 of the present invention can induce an increase in various cytokines such as interferon in peripheral blood, have excellent inhibitory effects on tumors such as melanoma, and improve survival time. The combination of the compound LD002 of the present invention with anti-PD-L1 has a synergistic effect on tumor growth inhibition and improvement of survival time. Therefore, the compound of the present invention, as a drug that induces various cytokines such as interferon, can have antitumor effects and the function of promoting tumor immunotherapy.
[0130] Example 6. Compound LD002 of the present invention having immune adjuvant activity The experiment was divided into blank group (injected with the same amount of PBS), antigen group and antigen / compound of the present invention group (containing various concentration gradients) with 5 mice in each group. Antigen ovalbumin OVA and compound of the present invention LD002 were dissolved in PBS to obtain antigen solution and compound of the present invention solution, respectively, and solutions containing antigen and compound of the present invention with various concentration gradients were prepared according to the concentration requirements. Each mouse in the experimental group was immunized with 100 μl of antigen solution or antigen solution and LD002 solution each time. The immunization method was intramuscular injection. The mice in the blank group were injected with the same amount of PBS solution as the experimental group. The first immunization was set as day 0, and booster immunization was performed once on days 7 and 14, respectively. After the immunization was completed on day 21, blood was collected from the mouse orbit, mouse serum was collected, and after dilution, the antibody content in the mouse serum was detected by ELISA. The results show that, compared with the antigen group, immunization with OVA alone cannot generate protective humoral immune responses, and immunization of mice with OVA in combination with the compounds of the present invention can significantly increase the total amount of OVA-specific IgG, IgG1 and IgG2b antibodies, indicating that the compounds of the present invention have significant immune adjuvant activity (Figure 12).
[0131] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. In the following examples, the experimental methods that do not show specific conditions are usually in accordance with conventional conditions or conditions recommended by manufacturers. Unless otherwise specified, percentages and parts are calculated by weight.
Claims
1. Use of a compound of formula I or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, for preparing an innate immunity activating drug, comprising: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from hydrogen, halogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an amino group, a hydroxy group, a mercapto group, a carboxy group, an alkoxy group, a cycloalkoxy group, a halogenated alkyl group, a cyano group, a sulfanyl group, a sulfonyl group, a sulfone group, a sulfoxide group, and a phosphate group, and the alkyl group, the cycloalkyl group, the alkoxy group, the cycloalkoxy group, the amino group, the heterocyclyl group, the aryl group, or the heteroaryl group may be substituted with one or more substituents, and the substituents ... and wherein the heterocyclyl group is selected from one or more of the following substituents: aryl, aryl, halogenated aryl, halogenated alkyl, heteroaryl, alkenyl, alkynyl, amino, mercapto, carboxy, ester, alkoxycarbonyl, acyloxy, acylamino, carbamide, alkylsulfonyl, aromaticsulfonyl, cyano, nitro, nitroso, thiocyanato, isothiocyanato, sulfanyl, sulfonyl, phosphate, phosphonate, alkylphosphate, alkylphosphonate, arylphosphate, arylphosphonate, or null, and the heterocyclyl group contains at least one N atom or contains 1, 2, or 3 heteroatoms arbitrarily selected from N, S, and O.
2. The compound of formula I is characterized in that it comprises the compound 2. The use according to claim 1.
3. The pharma- ceutically acceptable salts of the compounds of formula I include the following salts:
3. Use according to claim 1 or 2.
4. The innate immune activating drug is (a) a broad spectrum antiviral drug; (b) an antitumor drug; and (c) a drug for preventing and / or treating cancer; (d) a drug for treating or preventing a type I interferon-associated disease; and (e) an immune adjuvant; and and / or (f) a cytokine-inducing agent.
2. The use according to claim 1.
5. The immune adjuvant is characterized in that it is used to prepare antibodies, vaccines, immunotherapeutic agents and / or immune activators.
5. The use according to claim 4.
6. 1. A broad spectrum antiviral pharmaceutical composition comprising: The broad spectrum antiviral pharmaceutical composition, characterized in that it comprises a compound of formula I as defined in claim 1 or 2 or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.
7. 1. An immunological composition comprising: The immune composition is characterized in that it comprises a compound of formula I according to claim 1 or 2 or a tautomer, meso form, racemate, enantiomer, diastereomer, or mixture form thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, and an antigen.
8. An antitumor pharmaceutical composition comprising: The pharmaceutical composition is characterized in that it comprises a compound of formula I according to claim 1 or 2 or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.
9. 1. A composition comprising: The composition comprises: (a) a first active ingredient which is a compound of Formula I, or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof; and (b) a therapeutically effective amount of a second active ingredient comprising an immunotherapy activator, a type I interferon modulator, or an antiviral agent.
10. A kit comprising: The kit comprises: (A) a first formulation comprising a first active ingredient which is a compound of Formula I, or a tautomer, meso-isomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof; and (B) a second formulation comprising a second active ingredient comprising an immunotherapy activator, a type I interferon modulator, or an antiviral agent.
11. It is used to prepare a natural immune activating drug, the drug comprising: (a) a broad spectrum antiviral drug; (b) an antitumor drug; and (c) a drug for preventing and / or treating cancer; (d) a drug for treating or preventing a type I interferon-associated disease; and (e) an immune adjuvant; and and / or (f) a cytokine-inducing agent. Use of the composition according to claim 9 or the kit according to claim 10.
12. A compound of formula I, or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from hydrogen, halogen, an alkyl group, a cycloalkyl group, an aryl group, a heteroaryl group, a heterocyclyl group, an alkenyl group, an alkynyl group, an amino group, a hydroxy group, a mercapto group, a carboxy group, an alkoxy group, a cycloalkoxy group, a halogenated alkyl group, a cyano group, a sulfanyl group, a sulfonyl group, a sulfone group, a sulfoxide group, and a phosphate group, and the alkyl group, the cycloalkyl group, the alkoxy group, the cycloalkoxy group, the amino group, the heterocyclyl group, the aryl group, or the heteroaryl group may be substituted with one or more substituents, and the substituents ... a heterocyclyl group, an aryl group, a halogenated aryl group, a halogenated alkyl group, a heteroaryl group, an alkenyl group, an alkynyl group, an amino group, a mercapto group, a carboxy group, an ester group, an alkoxycarbonyl group, an acyloxy group, an acylamino group, a carbamide group, an alkylsulfonyl group, an aromatic sulfonyl group, a cyano group, a nitro group, a nitroso group, a thiocyanato group, an isothiocyanato group, a sulfanyl group, a sulfonyl group, a phosphoric acid group, a phosphonic acid group, an alkyl phosphoric acid group, an alkyl phosphonic acid group, an aryl phosphoric acid group, an aryl phosphonic acid group, or a null group, wherein the heterocyclyl group contains at least one N atom or contains one, two or three heteroatoms arbitrarily selected from N, S and O.
13. The compounds of formula I are characterized in that they include the following compounds:
14. The pharma- ceutically acceptable salts of the compounds of formula I include the following salts:
13. The compound of claim 12.
Citation Information
Patent Citations
Medicament with broad-spectrum antiviral activity
CN113842386A
Drug for resisting novel coronavirus
CN113940933A
Interferon-inducing compounds and uses thereof
WO2011094693A1
